search
Back to results

Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium

Primary Purpose

Barrett's Esophagus, Esophageal Cancer

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Cryoballoon Ablation
Sponsored by
Pentax Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Barrett's Esophagus focused on measuring Esophagectomy, Barrett's Esophagus

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient must have a minimum of 2.0 cm of non-ulcerated, non-inflammatory columnar-lined esophagus or squamous esophageal lined tissue suitable for ablation. A patient may be treated with up to 2 zones of ablation.
  • Patient is 18 to 80 years of age at the time of consent (inclusive).
  • Patient has provided written Informed Consent Form (IFC) using a form that has been approved by the Institution's reviewing IRB/EC.
  • Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
  • Patient's esophagectomy is clinically necessary due to reasons unrelated to this study.
  • Patient is deemed operable per standard institutional criteria.

Exclusion Criteria:

  • Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to IFC, post treatment instructions or follow-up guidelines.
  • Patient refuses or is unable to provide written informed consent. - -
  • Patient has or is currently undergoing endoscopic ablation therapy within 4 cm from the proposed treatment area including, but not limited to cryospray therapy, laser treatment, photodynamic therapy, multi-polar electro coagulation, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
  • Patient has esophageal narrowing limiting access to the intended site of ablation.
  • Patient is undergoing or has recently undergone chemotherapy (within 15 days or WBC below normal by institutional criteria or standards).
  • Patient is undergoing or has recently undergone radiation therapy which involved the esophagus (within 15 days or WBC below normal by institutional criteria or standards).

Sites / Locations

  • University of Southern California
  • University of Rochester
  • University of Pittsburgh
  • AMC

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.

Outcomes

Primary Outcome Measures

Treatment effect
The primary outcome measure is to evaluate the histological results (depth of injury) of a cryoballoon ablation system.

Secondary Outcome Measures

Post-ablation symptoms
A secondary outcome measure is to evaluate post-ablation symptoms - number of participants with adverse events as a measure of safety and tolerability.
Post procedure pain
The secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale.

Full Information

First Posted
December 14, 2010
Last Updated
April 21, 2022
Sponsor
Pentax Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT01293448
Brief Title
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Official Title
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pentax Medical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
Detailed Description
The purpose of this study is to evaluate the histological results of a cryoablation technique used to ablate human esophageal mucosa. The performance and safety of the cryoablation technique will also be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett's Esophagus, Esophageal Cancer
Keywords
Esophagectomy, Barrett's Esophagus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
Intervention Type
Device
Intervention Name(s)
Cryoballoon Ablation
Other Intervention Name(s)
CryoBalloon Ablation System, cryoablation
Intervention Description
Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
Primary Outcome Measure Information:
Title
Treatment effect
Description
The primary outcome measure is to evaluate the histological results (depth of injury) of a cryoballoon ablation system.
Time Frame
Within 30 days of ablation procedure
Secondary Outcome Measure Information:
Title
Post-ablation symptoms
Description
A secondary outcome measure is to evaluate post-ablation symptoms - number of participants with adverse events as a measure of safety and tolerability.
Time Frame
Within 7 days of ablation procedure
Title
Post procedure pain
Description
The secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale.
Time Frame
Within 7 days of ablation procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must have a minimum of 2.0 cm of non-ulcerated, non-inflammatory columnar-lined esophagus or squamous esophageal lined tissue suitable for ablation. A patient may be treated with up to 2 zones of ablation. Patient is 18 to 80 years of age at the time of consent (inclusive). Patient has provided written Informed Consent Form (IFC) using a form that has been approved by the Institution's reviewing IRB/EC. Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements. Patient's esophagectomy is clinically necessary due to reasons unrelated to this study. Patient is deemed operable per standard institutional criteria. Exclusion Criteria: Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to IFC, post treatment instructions or follow-up guidelines. Patient refuses or is unable to provide written informed consent. - - Patient has or is currently undergoing endoscopic ablation therapy within 4 cm from the proposed treatment area including, but not limited to cryospray therapy, laser treatment, photodynamic therapy, multi-polar electro coagulation, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation. Patient has esophageal narrowing limiting access to the intended site of ablation. Patient is undergoing or has recently undergone chemotherapy (within 15 days or WBC below normal by institutional criteria or standards). Patient is undergoing or has recently undergone radiation therapy which involved the esophagus (within 15 days or WBC below normal by institutional criteria or standards).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacques Bergman, MD
Organizational Affiliation
AIDS Malignancy Consortium
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steve DeMeester, MD
Organizational Affiliation
University of Southern California
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Blair Jobe, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeffery Peters, MD
Organizational Affiliation
University of Rochester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
AMC
City
Amsterdam
State/Province
AZ
ZIP/Postal Code
1105
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium

We'll reach out to this number within 24 hrs